Advanced Solid Tumor Malignancies Clinical Trial
Official title:
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05791474 -
ATI-2231 in Advanced Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT00996515 -
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT01522989 -
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
|
Phase 1 |